Journal article icon

Journal article

Donepezil and memantine for moderate-to-severe Alzheimer's disease

Abstract:

Background

Clinical trials have shown the benefits of cholinesterase inhibitors for the treatment of mild-to-moderate Alzheimer’s disease. It is not known whether treatment benefits continue after the progression to moderate-to-severe disease.

Methods

We assigned 295 community-dwelling patients who had been treated with donepezil for at least 3 months and who had moderate or severe Alzheimer’s disease (a score of 5 to 13 on the Standardized Mini–Mental State Examin...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1056/NEJMoa1106668

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
RDM
Sub department:
RDM - Investigative Medicine Division
Role:
Author
Expand authors...
Medical Research Council More from this funder
Alzheimer’s Society More from this funder
Publisher:
Massachusetts Medical Society Publisher's website
Journal:
New England Journal of Medicine Journal website
Volume:
366
Issue:
10
Pages:
893-903
Publication date:
2012-03-08
DOI:
EISSN:
1533-4406
ISSN:
0028-4793
Source identifiers:
342959

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP